Suppliers / Gulbrandsen Technologies

Gulbrandsen Technologies

United States Updated 9 July 2026

Gulbrandsen Technologies is an API manufacturer based in United States. It holds one active US drug master file. Its most recent recorded inspection, by US FDA, closed on 16 February 2022 as VAI.

1
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 16 February 2022 VAI US FDA
  • 26 August 2015 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Orangeburg, United States 1000111095

What they file, and where

Molecule Regulators Docs
Sucralfate US FDA 1

Also appears on these molecule pages

Sucralfate API

Questions about Gulbrandsen Technologies

Does Gulbrandsen Technologies hold a US DMF or a CEP?
Gulbrandsen Technologies holds 1 active US drug master file. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Gulbrandsen Technologies FDA-registered?
One site operated by Gulbrandsen Technologies carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Gulbrandsen Technologies's last inspection go?
The most recent inspection on record closed on 16 February 2022 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 2 inspections are on file.
Where does Gulbrandsen Technologies manufacture?
1 registered site is on record, in United States (Orangeburg). Every site is listed on this page with the register it came from.
What does Gulbrandsen Technologies make?
1 molecule is on record against Gulbrandsen Technologies, including Sucralfate. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Gulbrandsen Technologies comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 16 February 2022.

Comparable suppliers

Alivus Life Sciences shares 1 molecule Archimica shares 1 molecule SNJ Labs shares 1 molecule Zhejiang Haisen Pharmaceutical shares 1 molecule Fuji Chemical Industries shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability